PT - JOURNAL ARTICLE AU - Wondimeneh shibabaw shiferaw AU - Tadesse Yirga Akalu AU - Mihretie Gedefaw AU - Yared Asmare Aynalem AU - Denis Anthony AU - Ayelign Mengesha AU - Worku Misganaw AU - Henok Mulugeta AU - Getenet Dessie TI - Metabolic syndrome among type 2 diabetic patients in Sub-Saharan African countries: a systematic review and meta-analysis AID - 10.1101/2020.05.14.20101410 DP - 2020 Jan 01 TA - medRxiv PG - 2020.05.14.20101410 4099 - http://medrxiv.org/content/early/2020/05/19/2020.05.14.20101410.short 4100 - http://medrxiv.org/content/early/2020/05/19/2020.05.14.20101410.full AB - Background Metabolic syndrome is one of the serious public health problems among type 2 diabetic patients. Despite a number of studies have been conducted, there is no overall estimation on the prevalence of metabolic syndrome among type 2 diabetic patients in Sub-Saharan African countries. Therefore, this study aimed to estimate the pooled prevalence of metabolic syndrome in patients with type 2 diabetes mellitus in Sub –Saharan African countries.Methods PubMed, Web of Science, African Journals Online, Google Scholar, Scopus, and Wiley Online Library databases from inception to April 27, 2020 were searched to identify relevant studies. The I2 statistic was used to check heterogeneity across the included studies. DerSimonian and Laird random-effects model was applied to estimate pooled effect size, and 95% confidence interval across studies. A funnel plot and Egger’s regression test were used to determine the presence of publication bias. Sensitivity analysis was deployed to determine the effect of a single study on the overall estimation. All statistical analyses were done using STATA™ Version 14 software.Result In this meta-analysis, a total of 23 studies with 6,482 study participants were included. The estimated prevalence of metabolic syndrome in Sub-Saharan African countries was 59.62% (95% CI: 52.20, 67.03). Based on the subgroup analysis, the highest prevalence of metabolic syndrome (61.14%, 95% CI: 51.74, 70.53) was reported in Ethiopia. . Additionally, the highest prevalence of metabolic syndrome was reported across studies using the diagnostic criteria of National Cholesterol Education Program Adult Treatment Panel III 64.8% (95% CI: 54.74, 74.86), followed by International Diabetic Federation (57.15%), and World health Organization (53.12%) definitions.Conclusion Almost two out of three type 2 diabetic patients in Sub-Saharan African countries have metabolic syndrome, which implies that its prevalence is high in patients with T2DM. Therefore, Policymakers (FMoH) need to design efficient strategies and guideline to reduce and control the burden of metabolic syndrome and its impact among diabetic population.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNot applicableAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data are within the paper and it’s supporting information files. There is no separate data set to shareIDFInternational diabetic federationMetsmetabolic syndromeNCEP ATP IINational Cholesterol Education Program Adult Treatment Panel IIIT2DMtype 2 diabetes mellitusWHOworld health organization